OP-ANNO180096 51..67

Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University Hospital Essen, Essen, Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy; Klinikum Stuttgart-Olgahospital, Stuttgart, Germany; Institut Curie, Paris, France; NORDIX, Athens, Greece; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Vienna General Hospital (AKH), Medizinische Universität Wien, Vienna, Austria; Hospital Universitario Virgen del Rocio-CIBERONC, Seville, Spain; Centro di Riferimento Oncologico di Aviano, Aviano; Ospedale Regionale di Treviso “S.Maria di Cà Foncello”, Treviso, Italy; Integrated Unit ICO Hospitalet, HUB, Barcelona, Spain; Sarcoma Unit, University College London Hospitals, London, UK; Skane University Hospital-Lund, Lund, Sweden; N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation; Institute of Scientific Hospital Care (IRCCS), Regina Elena National Cancer Institute, Rome; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Istituto Ortopedico Rizzoli, Bologna; Azienda Ospedaliera Universitaria Careggi Firenze, Florence, Italy; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; Institut Jules Bordet, Brussels, Belgium; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Italy; Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam and Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands; Turku University Hospital (Turun Yliopistollinen Keskussairaala), Turlu, Finland; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Mannheim University Medical Center, Mannheim; Department of Medicine III, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Helsinki University Central Hospital (HUCH), Helsinki, Finland; Royal Marsden Hospital, London; The Institute of Cancer Research, London, UK; University Medical Center Groningen, Groningen; Radboud University Medical Center, Nijmegen, The Netherlands; University Hospital Motol, Prague; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Gustave Roussy Cancer Campus, Villejuif, France; Maria Skłodowska Curie Institute, Oncology Centre, Warsaw, Poland; Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel; Medical Oncology, University Hospital of Lausanne, Lausanne, Switzerland; Azienda Ospedaliera, Universitaria, Policlinico S Orsola-Malpighi Università di Bologna, Bologna; Azienda Ospedaliero, Universitaria Cita della Salute e della Scienza di Torino, Turin, Italy; Fundacio de Gestio Sanitaria de L’hospital de la SANTA CREU I Sant Pau, Barcelona, Spain; Helios Klinikum Berlin Buch, Berlin, Germany; YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Sheffield, UK; Aarhus University Hospital, Aarhus, Finland; Leuven Cancer Institute, Leuven, Belgium; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Institute of Oncology of Ljubljana, Ljubljana, Slovenia; Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands; University College Hospital, London, UK; Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Münster, Germany; Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway; Centre Leon Bernard and UCBL1, Lyon, France

[1]  Robin L. Jones,et al.  Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Robin L. Jones,et al.  Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Blay,et al.  Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[4]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Blay,et al.  An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Bonvalot,et al.  Post‐relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans‐Atlantic RPS Working Group , 2017, Cancer.

[7]  J. Blay,et al.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.

[8]  P. Rutkowski,et al.  Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  M. Nucci,et al.  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. , 2017, Gynecologic oncology.

[10]  G. Rauch,et al.  Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). , 2017, European journal of cancer.

[11]  J. Blay,et al.  REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis , 2017, Cancer.

[12]  L. Mariani,et al.  Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis , 2017, Cancer journal.

[13]  Robin L. Jones,et al.  Pazopanib, a promising option for the treatment of aggressive fibromatosis , 2017, Anti-cancer drugs.

[14]  G. Bifulco,et al.  Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. , 2017, Gynecologic oncology.

[15]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[17]  F. Grosso,et al.  Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database , 2016, Annals of Surgical Oncology.

[18]  L. Qin,et al.  Efficacy of sorafenib in patients with desmoid-type fibromatosis. , 2016 .

[19]  S. Bonvalot,et al.  Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group , 2016, Annals of surgery.

[20]  L. Mariani,et al.  Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. , 2016, The Lancet. Oncology.

[21]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[22]  Jonathan M. Morris,et al.  Percutaneous Cryoablation of Extraabdominal Desmoid Tumors: A 10-Year Experience. , 2016, AJR. American journal of roentgenology.

[23]  T. Group,et al.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group , 2016, Annals of Surgical Oncology.

[24]  B. Seddon,et al.  GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). , 2015 .

[25]  S. Bonvalot,et al.  Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis , 2014, The British journal of surgery.

[26]  U. Mansmann,et al.  Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study , 2014, Annals of surgery.

[27]  J. Larkin,et al.  A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. , 2014, Anticancer research.

[28]  S. Steinberg,et al.  Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial , 2014, Annals of Surgical Oncology.

[29]  P. Dileo,et al.  What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.

[30]  P. Schwartz,et al.  Hormonal Therapy for Aggressive Angiomyxoma: A Case Report and Proposed Management Algorithm , 2014, Journal of lower genital tract disease.

[31]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[32]  C. Nezhat,et al.  Evaluating the risks of electric uterine morcellation. , 2014, JAMA.

[33]  C. Mussi,et al.  Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  K. Rankin,et al.  Preoperative Versus Postoperative Radiotherapy in Soft-Tissue Sarcoma of the Limbs: A Randomised Trial , 2014 .

[35]  T. Group,et al.  Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group , 2014, Annals of Surgical Oncology.

[36]  Robin L. Jones,et al.  Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.

[37]  J. Rauh-Hain,et al.  Endometrial Stromal Sarcoma: A Systematic Review , 2013, Obstetrics and gynecology.

[38]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[39]  S. Steinberg,et al.  Cediranib for metastatic alveolar soft part sarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Luigi Mariani,et al.  Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Wathen,et al.  Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.

[42]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[43]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[44]  A. D. Dei Tos,et al.  Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Verweij,et al.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[46]  T. Nielsen,et al.  Pazopanib for metastatic soft-tissue sarcoma , 2012, The Lancet.

[47]  J. Blay,et al.  Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  L. Mariani,et al.  Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  J. Blay,et al.  Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis , 2012, Cancer.

[50]  A. D. Dei Tos,et al.  Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Li-Xuan Qin,et al.  A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant Radiation , 2012, Annals of surgery.

[52]  A. D. Dei Tos,et al.  Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Steven J. M. Jones,et al.  14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma , 2012, Proceedings of the National Academy of Sciences.

[54]  P. Ip,et al.  Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[55]  A. Eggermont,et al.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[58]  Peter Wust,et al.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.

[59]  C. Antonescu,et al.  Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) , 2010, Cancer.

[60]  C. Antonescu,et al.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[62]  J. Roth,et al.  Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.

[63]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  P. Casali,et al.  Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.

[65]  J. Thigpen.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study , 2009 .

[66]  J. Blay,et al.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  F. Farrokhyar,et al.  A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.

[69]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[70]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[72]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  R. Sylvester,et al.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .

[77]  E. Casper,et al.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Cesne,et al.  High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[81]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.